Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Genmab (0MGB)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1,972.50 -24.00    -1.20%
- Real-time Data. Currency in DKK ( Disclaimer )
  • Volume: 607
  • Bid/Ask: 1,942.50 / 2,029.00
  • Day's Range: 1,970.00 - 1,990.50
Type:  Equity
Market:  United Kingdom
ISIN:  DK0010272202 
SEDOL:  B28HC00
Genmab 1,972.50 -24.00 -1.20%

0MGB Share Price Overview

 
Assess today's live Genmab (GMAB) share price, performance and insights using our live Copenhagen: GMAB stock exchange data.

Analyse the historical data and Genmab share price performance charts on this page. Our technical summary section provides analysis on Genmab share price buy/sell indicators using real-time data (or discuss the Genmab (GMAB) stock price today with other investors in the Genmab CSE share price and sentiment chat forum).

Use the dropdown to select a relevant stock exchange for the current CSE GMAB share price (ISIN: DK0010272202) to enhance your trading decisions with our free investment tools and resources.

What Is the Genmab Share Price Today?
The Genmab share price today is 1,972.50.

What Is the Stock Symbol for Genmab
The stock symbol (or 'ticker') for Genmab is "GMAB."

What Stock Exchange Does Genmab Trade On?
Genmab is listed and trades on the Copenhagen stock exchange.

Is Genmab a Good Stock to Buy?
Determining whether Genmab—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Loading
Last Update:
  • 1 Day
  • 1 Week
  • 1 Month
  • 3 Months
  • 6 Months
  • 1 Year
  • 5 years
  • Max
Prev. Close1,996.5
Day's Range1,970 - 1,990.5
Revenue16.47B
Open1,986.5
52 wk Range1,824.5 - 2,936
EPS66.64
Volume607
Market Cap128.35B
Dividend (Yield)N/A (N/A)
Average Volume (3m)45,066
P/E Ratio29.73
Beta0.764
1-Year Change - 27.86%
Shares Outstanding65,001,326
Next Earnings DateMay 02, 2024
What is your sentiment on Genmab?
or
Vote to see community's results!

Technical Summary

Type 5 Min 15 Min Hourly Daily Monthly
Moving Averages Strong Sell Strong Sell Strong Sell Strong Sell Strong Sell
Technical Indicators Strong Sell Strong Sell Strong Sell Strong Sell Strong Sell
Summary Strong Sell Strong Sell Strong Sell Strong Sell Strong Sell

Candlestick Patterns

 

Filter Table By:

Candle Sticks Characteristics:

Time Frame
Type
Pattern Indication
Reliability
Pattern Timeframe Reliability Candles Ago Candle Time
Emerging Patterns
Belt Hold Bullish 15 Current
Belt Hold Bullish 30 Current
Inverted Hammer 1D Current
Completed Patterns
Bullish Engulfing 1M 1 Mar 24
Morning Doji Star 1M 1 Mar 24
Morning Star 1M 1 Mar 24

Genmab Quotes

Exchange Last Bid Ask Volume Change % Currency Time
  Copenhagen 1,971.0 0.0 0.0 16,039 -1.18% DKK  
  BATS Europe 1,994.00 1,974.00 2,014.00 0 0.00% DKK  
  NASDAQ 28.33 28.00 28.74 242,491 -0.70% USD  
  London 1,972.50 1,942.50 2,029.00 607 -1.20% DKK  
  Vienna 266.00 262.80 266.00 0 +0.00% EUR  

Trending Stocks

Create Alert
Add to Watchlist
Add to/Remove from a Portfolio  
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

  Name Last High Low Chg. Chg. % Vol. Time
  IAG 165.16 166.45 162.15 -4.64 -2.73% 4.43M  
  EasyJet 517.06 529.00 515.80 -12.94 -2.44% 506.55K 08:54:48  
  Rolls-Royce Holdings 395.15 399.00 392.80 -7.35 -1.83% 1.81M 08:55:11  
  Lloyds Banking 50.40 50.83 50.28 -0.60 -1.18% 9.29M 08:55:01  
  Ocado 345.00 346.90 343.00 -5.00 -1.43% 100.04K 08:54:57  
  BP 511.10 514.40 510.50 -1.30 -0.25% 2.16M 08:54:58  
  BAE Systems 1,289.50 1,290.50 1,280.50 +2.50 +0.19% 490.41K 08:55:05  
  Centamin 127.20 128.40 126.60 -0.90 -0.70% 488.89K 08:53:28  
  HSBC 634.80 636.90 633.80 -9.80 -1.52% 2.39M 08:54:39  
  Barclays 182.08 182.90 181.50 -1.90 -1.03% 4.02M 08:54:37  

%SHORT_NAME% Company Profile

IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

2132

Equity Type

DRC

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Read More
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

GMAB Price Commentary

Write your thoughts about Genmab A/S
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email